Frontlight ResearchEarly access
CompletedPhase 1
A phase I trial to assess safety and immunogenicity of an HLAII-targeted DNA vaccine against influenza H7N9
Key facts
- Who runs it
- Oslo University Hospital Hf
- Where
- Norway1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 1
- People taking part
- 30 people enrolled
- Started
- 11 Sept 2023
- Ended
- 13 Apr 2026
- Type of study
- Interventional
- Record updated
- 22 June 2026
Who can take part
- Age
- 18 years to 64 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
Where is this trial?
It has sites in one country. Choose a country to see its sites.
Data and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 22 June 2026